Top

Kai Cao, MS, MD, F(ACHI)

Department of Laboratory Medicine, Division of Pathology-Lab Medicine Div

About Dr. Kai Cao

Part I: After long waiting for chance to college during a period of college-less years while working on farms as a teen, I finally stepped into a medical school following my parent’s insistence, but I loved it except for some scary feelings in anatomy class or in surgical rooms. Part II: Can you imagine what I must have felt when I first landed in a foreign country as a shy, timid, directionless, not-so-independent lady all alone having to leave husband and son behind, being corralled through to the seventh platform in a train station with two big luggage, a few small bags and then finally getting to the exit only to see all these strangers faces? Surprisingly, I survived beyond my expectations! Part III: Following that, coming to the United States was a much easier experience than I expected, although there wasn’t much drama, there were a few fears. But all that was years ago. Part IV: I’m very lucky to have a handsome, loving husband and a wonderful son. I love reading novels, like music & exercises, love movies and dancing, with the Argentine tango being my favorite. I dreamed of playing the piano, but never had the chance or luxury to learn. I love my work! I have been fortunate to have the opportunities to work for a few famous institutions. My family and I moved to warmer temperatures bounding from the east (Maryland) to the west (California) and now, to the south (Texas) where I call home.

Primary Appointment

Program Director (authorized GSBS program), Department of Laboratory Medicine, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Section Chief, HLA Typing Laboratory, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

HLA polymorphism identification and differentiation methodologies, HLA gene frequencies in different ethnic groups, HLA haplotype frequencies, population distribution.

HLA and diseases association studies

Identification of new HLA genes (alleles), compile and report rare HLA alleles.

Killer Immunoglobulin-like Receptor (KIR): polymorphism, typing methodologies, KIR haplotypes, KIR HLA ligand mismatching and their impact on allogeneic hematopoietic stem cell and umbilical cord blood transplantation.

Clinical Interests

HLA matching and graft outcome in hematopoietic stem cell and umbilical cord blood unit transplantation.

NK cell benefit from selected donors to patients through graft-versus-leukemia effect in hematopoietic stem cell or umbilical cord blood unit transplantation.

Impact of anti-HLA antibodies in patients who need related or unrelated allogeneic hematopoietic stem cell transplantation. Anti-HLA antibody monitoring in these patients for guiding patients’ preemptive immune therapeutic treatment, optimal donor selection and monitoring post transplant.

Education & Training

Degree-Granting Education

1990	China Medical University, Shenyang, CN, M.S. in Dermatology
1982	China Medical University, Shenyang, CN, MD

Postgraduate Training

1992-1993	Clinical Fellowship, Histocompatibility and Immunogenetics, Laboratory of Immunogenetics, National Institute of Cancer Research, Genoa
1992-1993	Clinical Fellowship, Histocompatibility and Immunogenetics, S. Martini Hospital & University, Genoa
1991-1992	Certificate, Italian, Foreign Language Training Center, Beijing Language Institute, Beijing

Licenses & Certifications

2010	Fellow of The American College of Histocompatibility and Immunogenetics F(ACHI)
2006	Histocompatibility Specialist (CHS) of The American Board of Histocompatibility and Immunogenetics (ABHI)

Experience & Service

Administrative Appointments/Responsibilities

Program Director (authorized GSBS program), Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present

Section Chief, HLA Typing Laboratory, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present

Other Professional Positions

Associate Director, Cedars-Sinai Medical Center, Los Angeles, CA, 2011 - 2012

Assistant Director, Cedars-Sinai Medical Center, Los Angeles, CA, 2007 - 2011

Research Instructor, C.W. Bill Young/Department of Defense Marrow, Donor Program, Naval Medical Research Center/Georgetown University, Rockville, MD, 2001 - 2007

DNA Officer, American Red Cross, National Histocompatibility Laboratory, University of Maryland Medical System, Baltimore, MA, 2000 - 2001

Scientist I, American Red Cross, National Histocompatibility Laboratory, University of Maryland Medical System, Baltimore, MD, 1997 - 2000

Research Associate, American Red Cross, National Histocompatibility Laboratory, University of Maryland Medical System, Baltimore, MD, 1996 - 1997

Research Assistant, National Histocompatibility Laboratory of the American Red Cross, Rockville, MD, 1994 - 1996

Research Fellow I, National Histocompatibility Laboratory of the American Red Cross, Rockville, MD, 1993 - 1994

Visiting Scientist, Immunogenetics Laboratory, National Cancer Institute, Genoa, 1992 - 1993

Attending Doctor/Lecturer, Department of Dermatology and Immunology, No. 1 Hospital, China Medical University, Shenyang, 1990 - 1992

Physician, Department of Dermatology, No. 3 Hospital, China Medical University, Shenyang, 1983 - 1987

Extramural Institutional Committee Activities

Associate Member, Clinical Faculty Review Committee (CFRC-A), The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Faculty Wellness Working Group; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2023 - Present

Committe Member, Academic Review Committee for the Division of Education and Training, The University of Texas MD Anderson Cancer Center, 2022 - 2025

Faculty Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2025

Member, Division of Pathology and Laboratory Medicine Promotion and Tenure Advisory Committee (PTAC), The University of Texas MD Anderson Cancer Center, 2020 - Present

Associate Member, Clinical Faculty Review Committee (CFRC), The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Stem Cell Haploidentical Transplant Review Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2020

Member, Working Group for CFA Service Excellence Criteria, UT MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, 2016

Member, Clinical Faculty Review Committee (CFRC), The University of Texas MD Anderson Cancer Center, 2015 - 2018

Councilor for Bone Marrow, Bone Marrow Transplantation Councilor, Texas Transplantation Society, Inc, 2014 - 2017

Member, American Board of Histocompatibility & Immunogenetics, The University of Texas MD Anderson Cancer Center, 2013 - 2017

Judge or Abstract Reviewer, Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Graduate Medical Education, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, GME Curriculum Subcommittee, The University of Texas MD Anderson Cancer Center, 2012 - 2015

Member, Allogeneic Transplant Review Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Stem Cell Transplantation & Cellular Therapy Program Quality Management Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2020

Member, Stem Cell Transplant Graft Failure Review Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2020

Member, Kidney Patient Selection Committee, Cedars-Sinai Medical Center, 2007 - 2012

Member, Heart and Lung Transplant Committee, Cedars-Sinai Medical Center, 2007 - 2012

Member, Donor Selection Committee, Cedars-Sinai Medical Center, 2007 - 2012

Member, Bone Marrow Transplant Committee, Cedars-Sinai Medical Center, 2007 - 2012

Member, Transplant Immunotherapy Kidney Patient (TIP) Committee, Cedars-Sinai Medical Center, 2007 - 2012

Honors & Awards

2024	Excellence in Science 2024; MD Anderson Wall of Science; Quarter 2 (Dec 2023- Feb 2024), University of Texas MD Anderson Cancer Center
2020	Excellence in Science 2020. MD Anderson Wall of Science, Quarter 2 (Dec 2019-Feb 2020), University of Texas MD Anderson Cancer Center
2015 - 2027	Multi-Year Appointment Award, Clinical Faculty Appointment, UT MD Anderson Cancer Center
2013 - 2014	Honorary Executive, The International Association of Administrative Professionals
1999	Innovative Thinking Award, National Headquarters of the American Red Cross
1998	First Level Award for Employee Excellence in Professional/Technical Service, American Red Cross
1995	Incentive Award, National Headquarters of the American Red Cross

Professional Memberships

Texas Transplantation Society 2017 Program Committee

2016 - 2017

American Society of Hematology (ASH#1321899)

2015 - Present

American Board of Histocompatibility & Immunogenetics (ABHI)

2013 - 2017

American Society for Transplantation and Cellular Therapy, formerly the American Society for Blood & Marrow Transplantation (ASTCT ID#5650)

2012 - Present

Texas Transplantation Society (TTS#4132)

2012 - Present

College of American Pathologists (CAP)

2010 - Present

International Society for Heart and Lung Transplantation (ISHLT#30877)

2010 - 2016

American Society of Transplantation (AST#511428)

2009 - 2016

The American Society for Histocompatibility and Immunogenetics (ASHI)

2005 - Present

American Society of Histocompatibility and Immunogenetics (ASHI#10465)

1996 - Present

Selected Presentations & Talks

Local Presentations

2024. Optimal Donor Selection in Hematopoietic Stem Cell Transplantation. Invited. Houston Education Day; Houston HLA Meeting. Houston, Texas, US.
2015. Next Generation Sequencing (NGS),. Conference. Next Generation Sequencing (NGS),. Houston, TX, US.
2014. Characterization of Copy Number Variations (CNV) in the NKG2C Receptor Genes. Conference. Characterization of Copy Number Variations (CNV) in the NKG2C Receptor Genes. Houston, TX, US.
2014. Detection of “Weak” or Complement-fixing Anti-HLA Antibodies Using Solid Phase Immunoassays. Conference. Detection of “Weak” or Complement-fixing Anti-HLA Antibodies Using Solid Phase Immunoassays. Houston, TX, US.
2013. Diversification of HLA-ligands for Killer cell immunoglobulin-like receptor (KIR) genes in umbilical cord blood units could benefit patients in need of hematophoietic stem cell (HSC) transplant. Conference. Diversification of HLA-ligands for Killer cell immunoglobulin-like receptor (KIR) genes in umbilical cord blood units could benefit patients in need of hematophoietic stem cell (HSC) transplant. Houston, TX, US.
2013. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Conference. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Houston, TX, US.
2013. HLA polymorphism and transplantation. Conference. HLA polymorphism and transplantation. Houston, TX, US.
2012. Natural Killer Cells and Their Receptors. Conference. Natural Killer Cell and Their Receptors. Houston, TX, US.
2012. Natural Killer Cell Immunoglobulin-Like Receptors (KIR) and Stem Cell Transplantation. Conference. Natural Killer Cell Immunoglobulin-Like Receptors (KIR) and Stem Cell Transplantation. Houston, TX, US.
2012. Natural Killer Cell Receptor: NKG2C. Conference. Natural Killer Cell Receptor: NKG2C. Houston, TX, US.
2012. HLA Testing in Solid Organ Transplantation. Conference. HLA Testing in Solid Organ Transplantation. Houston, TX, US.
2012. Anti-angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor-Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complications in Heart Transplant. Conference. Anti-angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor-Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complications in Heart Transplant. Houston, TX, US.
2012. HLA polymorphism and Transplantation. Conference. HLA polymorphism and Transplantation. Houston, TX, US.
2012. Detection of Anti-HLA Antibody in Allogeneic bone marrow and hematopoietic stem cell transplant patients. Conference. Detection of Anti-HLA Antibody in Allogeneic bone marrow and hematopoietic stem cell transplant patients. Houston, TX, US.

Regional Presentations

2016. C1q DSA in Hematopoietic Stem Cell Transplantation. Conference. C1q DSA in Hematopoietic Stem Cell Transplantation. Fort Worth, TX, US.
2011. HLA testing in solid organ transplantation. Conference. HLA testing in solid organ transplantation. Los Angeles, CA, US.
2011. HLA polymorphism and transplantation. Conference. HLA polymorphism and transplantation. Los Angeles, CA, US.
2011. HLA testing in bone marrow and solid organ transplantation. Conference. HLA testing in bone marrow and solid organ transplantation. Los Angeles, CA, US.
2009. HLA polymorphism and transplantation. Conference. HLA polymorphism and transplantation. Los Angeles, CA, US.
2009. HLA polymorphism and transplantation. Conference. HLA polymorphism and transplantation. Los Angeles, CA, US.
2008. HLA Review. Conference. HLA Review. Los Angeles, CA, US.
2008. Stem Cell Engraftment Analysis Using PCR Amplification of VNTR/STR Loci. Conference. Stem Cell Engraftment Analysis Using PCR Amplification of VNTR/STR Loci. Los Angeles, CA, US.
2007. HLA DNA Methods, Gene and Haplotype Frequencies. Conference. HLA DNA Methods, Gene and Haplotype Frequencies. Los Angeles, CA, US.
2007. HLA DNA Methods, Gene and Haplotype Frequencies. Conference. HLA DNA Methods, Gene and Haplotype Frequencies. Los Angeles, CA, US.
2005. Decreased beads test using LABTypeTM SSO kits. Conference. Decreased beads test using LABTypeTM SSO kits. Rockville, MD, US.
2005. KIR genes and genotyping by reverse SSO methodology. Conference. KIR genes and genotyping by reverse SSO methodology. Rockville, MD, US.
2004. HLA Class I and II genes typing using reverse SSO with Luminex technology. Conference. HLA Class I and II genes typing using reverse SSO with Luminex technology. Rockville, MD, US.
2004. HLA Class I and II genes typing using reverse SSO with Luminex technology. Conference. HLA Class I and II genes typing using reverse SSO with Luminex technology. Rockville, MD, US.
2003. HLA Class I and II genes typing using LABTypeSSO(tm) with Luminex technology. Conference. HLA Class I and II genes typing using LABTypeSSO(tm) with Luminex technology. Rockville, MD, US.

National Presentations

2025. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. Conference. TCT Tandem Meetings 2025: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Abstract #62. Honolulu,, Hawaii, US.
2022. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Conference. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. New Orleans, LA, US.
2022. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Conference. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. New Orleans, LA, US.
2022. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Conference. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. New Orleans, LA, US.
2021. Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. Conference. Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies, US.
2021. Sirpα Mismatch Impacts Outcomes of Allogeneic Stem Cell Transplantation from HLA Matched Related Donor for Treatment of Lymphoid Malignancies. Conference. Sirpα Mismatch Impacts Outcomes of Allogeneic Stem Cell Transplantation from HLA Matched Related Donor for Treatment of Lymphoid Malignancies. Salt Lake City, UT, US.
2021. Results of a Phase I Study with Mb-IL21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Refractory Acute Myeloid Leukemia. Conference. Results of a Phase I Study with Mb-IL21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Refractory Acute Myeloid Leukemia, US.
2020. Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. (Oral Presentation). Conference. Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients withMultiple Relapsed and Refractory Acute Myeloid Leukemia. (Oral Presentation), US.
2020. Donor-specific anti-HLA antibodies (DSA) and graft outcome in hematopoietic cell transplantation. Workshop: HCT: Transplanting the sensitized patient. Conference. Donor-specific anti-HLA antibodies (DSA) and graft outcome in hematopoietic cell transplantation. Workshop: HCT: Transplanting the sensitized patient, US.
2020. IgG subclass in C1q+ antibodies in haploidentical HCT. Conference. IgG subclass in C1q+ antibodies in haploidentical HCT. Rancho Mirage, CA, US.
2020. Desensitization Therapy for Patients with DSA Receiving Haploidentical (Haplo) Stem Cell Transplantation. Conference. Desensitization Therapy for Patients with DSA Receiving Haploidentical (Haplo) Stem Cell Transplantation. Orlando, FL, US.
2019. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients, (Oral Presentation). Conference. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients, (Oral Presentation). Orlando, FL, US.
2019. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls, (Oral Presentation). Conference. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls, (Oral Presentation). Orlando, FL, US.
2019. Enhanced anti-tumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation. Conference. Enhanced anti-tumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation. Alexandria, VA, US.
2019. Role Killer cell immunoglobulin-like receptor (KIR)-ligand interactions are critical to prevent relapse in patients receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). Conference. Role Killer cell immunoglobulin-like receptor (KIR)-ligand interactions are critical to prevent relapse in patients receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). Alexandria, VA, US.
2019. Outcomes with High Doses of Vivo Expanded NK Cells after Haploidentical Stem Cell Transplantation (haploSCT). Conference. Outcomes with High-doses of vivo Expanded NK Cells after Haploidentical Stem Cell Transplantation (haploSCT), US.
2018. Complement-fixing antibody testing for hematopoietic stem cell transplant (HSCT) patients with donor-specific anti-HLA antibodies (DSA. Conference. Complement-fixing antibody testing for hematopoietic stem cell transplant (HSCT) patients with donor-specific anti-HLA antibodies (DSA. La Jolla, CA, US.
2018. Initial results of two-phase l trials delivering mblL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias. (Oral Presentation). Conference. Initial results of two phase l trials delivering mblL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias. (Oral Presentation). Chicago, IL, US.
2018. Phase ll study of ex vivo expanded cord blood natural killer cells for multiple myeloma. (Oral Presentation). Conference. Phase ll study of ex vivo expanded cord blood natural killer cells for multiple myeloma. (Oral Presentation). Chicago, IL, US.
2018. The influence of HLA testing in HSCT. Conference. The influence of HLA testing in HSCT, US.
2018. New era in HSCT: every patient has a donor. Conference. New era in HSCT: every patient has a donor, US.
2016. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Conference. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. San Diego, CA, US.
2016. Copy Number Variations (CNV) in the NKG2C Receptor Genes. Conference. Copy Number Variations (CNV) in the NKG2C Receptor Genes. Palm Springs, CA, US.
2015. Selective Pressure on HLA Haplotypes to Maximize Interaction with Natural Killer Cells. Conference. Selective Pressure on HLA Haplotypes to Maximise Interaction with Natural Killer Cells. Savannah, GA, US.
2015. Antibody Strength and Levels by C1q and SAB IgG. Conference. Antibody Strength and Levels by C1q and SAB IgG. Henderson, NV, US.
2014. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Conference. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. San Francisco, CA, US.
2014. Identification of Novel HLA Alleles by Sequence Based Typing (SBT): A*33:73N and C*03:218. Conference. Identification of Novel HLA Alleles By Sequernce Based Typing (SBT): A*33:73N and C*03:218. Denver, CO, US.
2014. Distribution of KIR HLA Ligands in Transplant Patients and Their Cord Blood Unit (CBU) Donors. Conference. Distribution of KIR HLA Ligands in Transplant Patients and Their Cord Blood Unit (CBU) Donors. Denver, CO, US.
2014. HLA Gene Mutagenesis Caused by Tumor Blast Cells in Peripheral Blood. Conference. HLA Gene Mutagenesis Caused by Tumor Blast Cells in Peripheral Blood. Denver, CO, US.
2014. Frequency of HLA-B*44:03-C*04:09N Bearing Haplotypes and Phenotypes in Leukemia Patients (oral). Conference. Frequency of HLA-B*44:03-C*04:09N Bearing Haplotypes and Phenotypes in Leukemia Patients (oral). Denver, CO, US.
2014. Serum Dilution Allows the Detection of “Weak” Anti-HLA Antibodies in Allogeneic Stem Cell Transplant Patients. Conference. Serum Dilution Allows the Detection of “Weak” Anti-HLA Antibodies in Allogeneic Stem Cell Transplant Patients. Tucson, AZ, US.
2014. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. Conference. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. San Francisco, CA, US.
2013. Diversify HLA-ligands (HLA-L) for killer cell immunoglobulin-like receptor (KIR) genes in umbilical cord blood units (UCBU) could benefit patients (PTS) in need of hematophoietic stem cells (HSC) transplant (Tx). Conference. Diversify HLA-ligands (HLA-L) for killer cell immunoglobulin-like receptor (KIR) genes in umbilical cord blood units (UCBU) could benefit patients (PTS) in need of hematophoietic stem cells (HSC) transplant (Tx). Chicago, IL, US.
2013. Identification of novel HLA alleles by sequence-based typing (SBT): A*01:114, A*02:397, A*11:129, A*32:46, B*44:160 and C*07:307. Conference. Identification of novel HLA alleles by sequence based typing (SBT): A*01:114, A*02:397, A*11:129, A*32:46, B*44:160 and C*07:307. Chicago, IL, US.
2013. Anti-HLA-Class-I antibodies and platelet transfusion refractoriness. Conference. Anti HLA-Class-I antibodies and platelet transfusion refractoriness. Chicago, IL, US.
2013. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Conference. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Orlando, FL, US.
2013. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Conference. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Salt Lake City, UT, US.
2013. Changes in HLA Antigens Is Not a Major Mechanism of Acute Myeloid Leukemia Relapse After Matched Allogeneic Stem Cell Transplantation (oral). Conference. Changes in HLA Antigens Is Not a Major Mechanism of Acute Myleoid Leukemia Relapse After Matched Allogeneic Stem Cell Transplantation (oral). Salt Lake City, UT, US.
2013. Anti-Angiotensin Type 1 Receptor Antibodies Associated with Rejection in Donor HLA Antibody Negative Recipients. Conference. Anti-Angiotensin Type 1 Receptor Antibodies Associated With Rejection In Donor HLA Antibody Negative Recipients, US.
2012. Detection of Anti-HLA Antibody in Allogeneic Bone Marrow and Hematopoietic Stem Cell Transplant Patients. Conference. Detection of Anti-HLA Antibody in Allogeneic Bone Marrow and Hematopoietic Stem Cell Transplant Patients. Honolulu, HI, US.
2011. Role of Anti-HLA antibody assessment and risk stratification in heart transplantation. Conference. Role of Anti-HLA antibody assessment and risk stratification in heart transplantation. New Orleans, LA, US.
2011. Identification of a novel DRB1*08:01 haplotype carrying DRB3*01:01 by molecular methods. Conference. Identification of a novel DRB1*08:01 haplotype carrying DRB3*01:01 by molecular methods. New Orleans, LA, US.
2011. C4d+ antibody mediated rejection in absence of complement fixing donor specific antibody for a heart transplant patient. Conference. C4d+ antibody mediated rejection in absence of complement fixing donor specific antibody for a heart transplant patient. New Orleans, LA, US.
2011. Infectious outcomes in kidney transplant recipients treated with IVIG and Rituximab (IVIG+RIT) for desensitization versus non-rituximab treated recipients. Conference. Infectious outcomes in kidney transplant recipients treated with IVIG and Rituximab (IVIG+RIT) for desensitization versus non-rituximab treated recipients. Philadelphia, PA, US.
2011. Antibody testing strategies for selection of deceased donors (DD) for broadly sensitized patients following pretransplant immunomodulatory therapy. Conference. Antibody testing strategies for selection of deceased donors (DD) for broadly sensitized patients following pretransplant immunomodulatory therapy. Philadelphia, PA, US.
2010. Tracking the impact of IVIG and Rituximab combination therapy on HLA antibody specificities and strengths. Conference. Tracking impact of IVIG and Rituximab combination therapy on HLA antibody specificities and strengths. San Diego, CA, US.
2010. Monitoring highly sensitized patients (HS) post-transplant (Tx) by intracellular cytokine flow cytometry (CFC) together with donor specific antibody (DSA) predicts risk of antibody mediated rejection (AMR) and allograft dysfunction. Conference. Monitoring highly sensitized patients (HS) post-transplant (Tx) by intracellular cytokine flow cytometry (CFC) together with donor specific antibody (DSA) predicts risk of antibody mediated rejection (AMR) and allograft dysfunction. San Diego, CA, US.
2010. Unique Approach for Identifying Compatible Donors for Lung Transplant Recipients with HLA Specific Antibodies Using the Virtual Crossmatch and Desensitization. Conference. Unique Approach for Identifying Compatible Donors for Lung Transplant Recipients with HLA Specific Antibodies Using the Virtual Crossmatch and Desensitization. Chicago, IL, US.
2010. Interrelationship between the sequential single antigen profiles. Conference. Interrelationship between the sequential single antigen profiles. Maui, HI, US.
2010. Impact of anti-HLA antibodies on heart transplant outcome. Conference. Impact of anti-HLA antibodies on heart transplant outcome. Maui, HI, US.
2009. Standardizing Luminex platform readers. Conference. Standardizing Luminex platform readers. San Francisco, CA, US.
2009. Identifying the optimal windows for transplantation through active surveillance of antibody levels after desensitization. Conference. Identifying the optimal windows for transplantation through active surveillance of antibody levels after desensitization. San Francisco, CA, US.
2009. Humoral responses to a non-HLA specific antigen. Angiotensin type I receptor (AT1R) are associated with early antibody mediated acute rejection (AMR). Conference. Humoral responses to a non-HLA specific antigen. Angiotensin type I receptor (AT1R) are associated with early antibody mediated acute rejection (AMR). San Francisco, CA, US.
2009. Identification of novel HLA alleles of A*9241, B*9546, B*350107 and Cw*0763 by sequence-based typing (SBT). Conference. Identification of novel HLA alleles of A*9241, B*9546, B*350107 and Cw*0763 by sequence-based typing (SBT). San Francisco, CA, US.
2009. Virtual Crossmatching by Flow Cytometry and Luminex Expands the Donor Pool and Potentially Shortens the Wait Time in Heart Transplant Candidates with Panel Reactive Antibody. Conference. Virtual Crossmatching by Flow Cytometry and Luminex Expands the Donor Pool and Potentially Shortens the Wait Time in Heart Transplant Candidates with Panel Reactive Antibody, US.
2009. Analysis of Subcutaneous (SQ) Campath 1-H Induction Therapy in Highly HLA Sensitized (HS) Patients Desensitization with IVIG + Rituximab: Three Year Outcomes. Conference. Analysis of Subcutaneous (SQ) Campath 1-H Induction Therapy in Highly HLA Sensitized (HS) Patients Desensitization with IVIG + Rituximab: Three Year Outcomes. Boston, MA, US.
2009. Paradigm for Predicting Risk of Antibody Mediated Rejection After Desensitization. Conference. Paradigm for Predicting Risk of Antibody Mediated Rejection After Desensitization. Boston, MA, US.
2009. HLA Mismatching Has No Significant Impact on Kidney Transplant Outcomes of Highly HLA Sensitized Patients with IVIG +/- Rituximab. Conference. HLA Mismatching Has No Significant Impact on Kidney Transplant Outcomes of Highly HLA Sensitized Patients with IVIG +/- Rituximab. Boston, MA, US.
2009. Characteristics of Patients Who Developed Antibody Mediated Rejection (AMR) Post-Transplant after Desensitization with IVIG + Rituximab: Analysis of Risk Factors & Outcomes. Conference. Characteristics of Patients Who Developed Antibody Mediated Rejection (AMR) Post-Transplant after Desensitization with IVIG + Rituximab: Analysis of Risk Factors & Outcomes. Boston, MA, US.
2009. Immunological Selection Criteria Identifying Patients for Successful Desensitization (DES) with IVIG and Rituxan. Conference. Immunological Selection Criteria Identifying Patients for Successful Desensitization (DES) with IVIG and Rituxan. Boston, MA, US.
2009. Monitoring Highly Sensitized Patients (HS) Post-Transplant (TX) by Intracellular Cytokine Flow Cytometry (CFC) Together with Donor Specific Antibody (DSA) and Pre-desensitization (PRE-DES) B Cell Crossmatch (B-CMX) Predicts Risk of Antibody Mediated Rejection (AMR). Conference. Monitoring Highly Sensitized Patients (HS) Post-Transplant (TX) by Intracellular Cytokine Flow Cytometry (CFC) Together with Donor Specific Antibody (DSA) and Pre-desensitization (PRE-DES) B Cell Crossmatch (B-CMX) Predicts Risk of Antibody Mediated Rejection (AMR). Boston, MA, US.
2009. Cellular Allo-Reactivity against Paternal HLA (PHLA) Antigens (AGS) in Multiparous Normal Females (NF) as Detected by Intracellular Cytokine Flow Cytometry (CFC) Remains Elevated over Years Despite Diminution of Anti-HLA Antibody (AB) Levels, Suggesting Allo-AG Specific Memory Cell Activity. Conference. Cellular Allo-Reactivity against Paternal HLA (PHLA) Antigens (AGS) in Multiparous Normal Females (NF) as Detected by Intracellular Cytokine Flow Cytometry (CFC) Remains Elevated over Years Despite Diminution of Anti-HLA Antibody (AB) Levels, Suggesting Allo-AG Specific Memory Cell Activity. Boston, MA, US.
2009. Long Term Outcomes of Deceased Donor (DD) Transplants in Highly HLA Sensitized Patients (HS) Desensitized with IVIG and Single-dose (SD) Rituximab. Conference. Long Term Outcomes of Deceased Donor (DD) Transplants in Highly HLA Sensitized Patients (HS) Desensitized with IVIG and Single-dose (SD) Rituximab. Boston, MA, US.
2009. Improving Organ Allocation for Highly Sensitized (HS) Heart (HT) and Kidney (KID) Recipients: Defining Criteria for Unacceptable Antigen (UA) Assignment Using a Calculated PRA (CPRA) and Flow Crossmatch (FXM) Trajectory. Conference. Improving Organ Allocation for Highly Sensitized (HS) Heart (HT) and Kidney (KID) Recipients: Defining Criteria for Unacceptable Antigen (UA) Assignment Using a Calculated PRA (CPRA) and Flow Crossmatch (FXM) Trajectory. Boston, MA, US.
2009. Long-Term Outcome in Highly HLA Sensitized (HS) Patients Receiving Desensitization with IVIG and Single-Dose (SD) Rituximab. Conference. Long Term Outcome in Highly HLA Sensitized (HS) Patients Receiving Desensitization with IVIG and Single-dose (SD) Rituximab. Boston, MA, US.
2009. Successful Virtual Crossmatches Increase Heart Transplantation of Sensitized Patients. Conference. Successful Virtual Crossmatches Increase Heart Transplantation of Sensitized Patients. Rancho Mirage, CA, US.
2009. Desensitization of Highly HLA-Sensitized Heart Transplant Candidates Using High-Dose Intravenous Immunoglobulin and Rituximab with Successful Transplantation. Conference. Desensitization of Highly HLA-Sensitized Heart Transplant Candidates Using High-Dose Intravenous Immunoglobulin and Rituximab with Successful Transplantation. Orlando, FL, US.
2008. HLA Antibody Identification Using Solid Phase Immunoassays to Monitor Changes in Donor Specific Antibodies. Conference. HLA Antibody Identification Using Solid Phase Immunoassays to Monitor Changes in Donor Specific Antibodies. Honolulu, HI, US.
1999. Molecular Typing of HLA-A, B, C, DRB1 Genes for Kidney Transplantation Donor-recipient Pairs of the United Network Organ Sharing (UNOS) Program by PCR-SSOP. Conference. Molecular Typing of HLA-A, B, C, DRB1 Genes for Kidney Transplantation Donor-recipient Pairs of the United Network Organ Sharing (UNOS) Program by PCR-SSOP. New Orleans, LA, US.
1997. Analysis of the linkage disequilibria between DNA-defined HLA class I alleles in five ethnic groups. Conference. Analysis of the linkage disequilibria between DNA-defined HLA class I alleles in five ethnic groups. Atlanta, GA, US.
1997. Novel alleles related to HLA-Cw*1601, Cw*0401 and Cw*0802 identified in the retrospective study of bone marrow transplant pairs organized by the National Marrow Donor Program (NMDP). Conference. Novel alleles related to HLA-Cw*1601, Cw*0401 and Cw*0802 identified in the retrospective study of bone marrow transplant pairs organized by the National Marrow Donor Program (NMDP). Atlanta, GA, US.
1996. DNA Typing of HLA-A Alleles in Five Ethnic Groups by PCR-SSOP. Conference. DNA Typing of HLA-A Alleles in Five Ethnic Groups by PCR-SSOP. San Diego, CA, US.
1996. DNA Typing of HLA-C Alleles in Five Ethnic Groups by PCR-SSOP. Conference. DNA Typing of HLA-C Alleles in Five Ethnic Groups by PCR-SSOP. San Diego, CA, US.

International Presentations

2016. Donor-Specific Anti-HLA Antibodies and Graft Outcome in Hematopoietic Stem Cell Transplantation. Conference. Donor-Specific Anti-HLA Antibodies and Graft Outcome in Hematopoietic Stem Cell Transplantation. Lisboa, PT.
2013. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies Together with De Novo Donor HLA Specific Antibodies on Graft Outcome in Heart Transplant Recipients. Conference. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies Together with De Novo Donor HLA Specific Antibodies on Graft Outcome in Heart Transplant Recipients. Montreal, CA.
2012. Identification of New HLA Alleles By Sequence Based Typing: B*40:206, C*02:58, DQB1*03:40, DQB1*06:50. Conference. Identification of New HLA Alleles by Sequence Based Typing: B*40:206, C*02:58, DQB1*03:40, DQB1*06:50. San Juan, PR.
2012. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complication in Heart Transplant. Conference. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) identify Patients at Risk for Immune Complication in Heart Transplant. Prague, CZ.
2011. HLA testing and bone Marrow and solid organ transplantation. Conference. HLA testing and bone Marrow and solid organ transplantation. Shenyang, CN.
2011. HLA gene typing and antibody detection in solid organ transplantation. Conference. HLA gene typing and antibody detection in solid organ transplantation. Shenyang, CN.
2011. Level of donor specific anti-HLA antibody and antibody mediated rejection in highly HLA-sensitized patients with kidney transplantation. Conference. Level of donor specific anti-HLA antibody and antibody mediated rejection in highly HLA sensitized patients with kidney transplantation. Punta Cana, DO.
2011. High CPRA is associated with earlier occurrence of AMR in kidney transplant patients. Conference. High CPRA is associated with earlier occurrence of AMR in kidney transplant patients. Punta Cana, DO.
2010. Non-HLA Glutathione-S-Transferase T1 (GSTT1) antibody among renal transplant patients. Conference. Non-HLA Glutathione-S-Transferase T1 (GSTT1) antibody among renal transplant patients. Vancouver, CA.
2010. Anti-Angiotensin Type 1 Receptor (AT1R) Antibody Associated with C4d+ Antibody Mediated Rejection (AMR) in Patients with No Donor HLA Specific Antibody (DHSA). Conference. Anti-Angiotensin Type 1 Receptor (AT1R) Antibody Associated with C4d+ Antibody Mediated Rejection (AMR) in Patients with No Donor HLA Specific Antibody (DHSA). Vancouver, CA.
2010. Single Predominant Engraftment of Double Umbilical Cord Blood Transplantations in Myelogenous Leukemia Patients. Conference. Single Predominant Engraftment of Double Umbilical Cord Blood Transplantations in Myelogenous Leukemia Patients. Vancouver, CA.
2009. No Significant Impact of HLA-Specific Antibodies (Ab) and Donor-Specific Antibodies (DSA) on Heart Transplant Outcome Subsequent to Thymoglobulin Induction. Conference. No Significant Impact of HLA-Specific Antibodies (Ab) and Donor-Specific Antibodies (DSA) on Heart Transplant Outcome Subsequent to Thymoglobulin Induction. Paris, FR.
2008. Impact of HLA Antibody on Mismatched Hematopoietic Stem Cell Transplants (HSCT) Outcome. Conference. Impact of HLA Antibody on Mismatched Hematopoietic Stem Cell Transplants (HSCT) Outcome, BR.
2008. Successful Deceased and Living Donor Kidney Transplantation after Desensitization Therapy in the Presence of Donor Specific Antibodies (DSA): Determination of Acceptable Pre- and Posttransplant DSA Levels. Conference. Successful Deceased and Living Donor Kidney Transplantation after Desensitization Therapy in the Presence of Donor Specific Antibodies (DSA): Determination of Acceptable Pre- and Posttransplant DSA Levels. Sydney, AU.
2008. HLA and Transplantations. Conference. HLA and Transplantations. Sheng Yang, CN.
1998. Retrospective Study of HLA-C Alleles in Donor and Recipient Samples Organized by the National Marrow Donor Program. Conference. Retrospective Study of HLA-C Alleles in Donor and Recipient Samples Organized by the National Marrow Donor Program. Vancouver, CA.
1998. DNA Typing of HLA-Bw4/Bw6 Related Alleles by Group-specific Amplifications and SSOP. Conference. DNA Typing of HLA-Bw4/Bw6 Related Alleles by Group-specific Amplifications and SSOP. Vancouver, CA.
1992. Study on the application of monoclone antibody for treating malignant lymphoma. Conference. Study on the application of monoclone antibody for treating malignant lymphoma, CN.
1991. Study of the function of HLA antigens on the identification of parents and offsprings. Conference. Study of the function of HLA antigens on the identification of parents and offsprings, CN.

Formal Peers

2011. HLA testing and bone marrow and solid organ transplantation. Invited. Shenyang, CN.
2011. HLA gene typing and antibody detection in solid organ transplantation. Invited. Shenyang, CN.
2010. Quantitative Detection and Monitoring of Anti-HLA Antibodies Using Solid Phase Immunoassays in Organ Transplantation. Invited. Houston, TX, US.
2008. HLA and Transplantations. Invited. Shengyang, P.R, CN.
2008. HLA and Transplantations. Invited. Shengyang, P. R, CN.
2002. DNA methods for HLA Typing. Invited. Shengyang, P.R, CN.

Less

Grant & Contract Support

Date:	2015 - 2020
Title:	Human Leukocyte Antigen (HLA) typing using Sirona HLA-Next Generation Sequencing (NGS) methodology
Funding Source:	Sirona
Role:	PI
ID:	PA15-0048

Date:	2013 - 2018
Title:	MD Anderson Start-Up Funds
Funding Source:	MDACC
Role:	PI

Date:	2012 - 2013
Title:	HLA-Null Allele Beta Test Study Plan
Funding Source:	GenProbe
Role:	Principal Investigator-MDACC
ID:	2012-00036702JW-01

Date:	2012 - 2015
Title:	Bio Fortuna Clinical Trial Protocol & Process V1.2 SSPGo HLA Genotyping Kits
Funding Source:	Biofortuna
Role:	PI
ID:	PA12-0882

Selected Publications

Peer-Reviewed Articles

Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B. Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide 40, 2026. PMID: 41803402.
Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
Dileo, oglesby, Leung, Pauken, Farooq, Haydu, Kubicki, Martinez, Welborn, Zahiruddin, Zou, Cao K, Patel. Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. Cancer: An International Interdisciplinary Journal of the American Cancer society 132(3):e70262, 2026. e-Pub 2026. PMID: 41563778.
Saliba, R.M, Niemann, M, Srour, S.A, Greenbaum, U, Alzahrani, K.K, Carmazzi, Y, Rondon, G, Rezvani, K, Daher, M, Li, D, Ma, Q, Tanner, M.R, Cao, K, Shpall, E.J, Champlin, R.E, Spierings, E, Zou, J. Molecular Disparity of HY Antigen Affects Chronic Graft-Versus-Host Disease and Relapse in Female-to-Male Stem Cell Transplants. Transplantation and Cellular Therapy 31(11):903–915, 2025. e-Pub 2025. PMID: 40714365.
Kongtim, P, Vittayawacharin, P, Zou, J, Srour, S, Shaffer, BC, Shapiro, R, Varma, A, McGuirk, J, Dholaria, B, McCurdy, SR, Dezern, A, Bejanyan, N, Bashey, A, Fürst, S, Castagna, L, Mariotti, J, Ruggeri, A, Bailen, R, Teshima, T, Xiao-Jun, H, Bonfim, C, Aung, FM, Cao, K, Carpenter, P, Hamadani, M, Askar, M, Fernandez-Vina, M, Girnita, A, Ciurea, SO. ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transplantation and Cellular Therapy 30(12):1139-1154, 2024. e-Pub 2024. PMID: 39260570.
Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DA. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol 99(5):890-899, 2024. e-Pub 2024. PMID: 38444268.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol 13:1033871, 2022. e-Pub 2022. PMID: 36311784.
Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol 13:904718, 2022. e-Pub 2022. PMID: 35874659.
Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica 107(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao K. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 5(20):4031-4043, 2021. e-Pub 2021. PMID: 34474478.
Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155-164, 2021. e-Pub 2021. PMID: 34312462.
Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2021. e-Pub 2021. PMID: 34135465.
Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, Srour S, Partlow D, Champlin RE, Cao K. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv 4(15):3474-3485, 2020. e-Pub 2020. PMID: 32726398.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Posititve Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
Oran, B, Champlin, RE, Wang, F, Jeyakumar, N, Garcia-Manero, G, Kantarjian, HM, Saliba, RM, Cao, K, Shpall, E, Alousi, AM, Mehta, RS, Popat, UR, Futreal, A, Takahashi, K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(1), 2019. e-Pub 2019. PMID: 31723997.
Cao, K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9(OCT):2444, 2018. e-Pub 2018. PMID: 30405633.
Ciurea SO, Cao, K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler AT. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant 54(5):784, 2018. e-Pub 2018. PMID: 30232413.
Ciurea SO, Bittencourt MCB, Milton DR, Cao, K, Kongtim P, Rondon G, Chen J, Konopleya M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Advances 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleya M, Dayer N, Cotes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
Ciurea S, Cao, K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor Specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation 53(5):1-14, 2018. e-Pub 2018. PMID: 29335625.
Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao, K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130(16):1857-1868, 2017. e-Pub 2017. PMID: 28835441.
Mehta RS, Saliba RM, Cao, K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao, K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood 128(24):2819-2823, 2016. e-Pub 2016. PMID: 27760759.
Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtime P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-Arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122 (2016)(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297 - 312, 2016. e-Pub 2016. PMID: 27247137.
Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase l Trial. Biology of Blood and Marrow Transplantation 22 (2016)(7):1290 - 1298, 2016. e-Pub 2016. PMID: 27090958.
Oran B, Cao K, Saliba RM, de Lima M, Sairah A, Hosint CM, Popat UR, Carmazzi Y, Kebriaei P, Kieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Rezvani K, Fernández-Viña M, Champlin RE. Better alelle-level matching improves transplant-related mortality after double cord blood transplantation for Hematologic Malignancy. Haematologica 100(10):1361-1370, 2015. e-Pub 2015. PMID: 26250579.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, Lopez AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernandez-Vina M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 21(8):1392-1398, 2015. e-Pub 2015. PMID: 25985919.
Liu L, Wu Y, Cao, K, Xu YY, Gao XH, Chen HD, Geng L. Shikonin inhibits IFN-y-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling. Int J Clin Exp Pathol 8 (8) (2015)(1936-2625):9202-9207, 2015. e-Pub 2015. PMID: 26464667.
Hamdi A, Cao, K, Poon LM, Aung F, Kornblau S, Fernandez Vina MA, Champlin RE, Ciurea SO. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?. Bone Marrow Transplantation 50 (2015)(3):411-413, 2015. e-Pub 2015. PMID: 25621795.
Reinsmoen NL, Lai CH, Mirocha J, Cao, K, Ong G, Naim M, Wang Q, Haas M, Rafiei M, Czer L, Patel J, Kobashigawa J. Increased Negative Impact of Donor HLA-Specific Together with Non-HLA-Specific Antibodies on Graft Outcome. Transplantation 97(5):595-601, 2014. e-Pub 2014. PMID: 24162250.
Fernández-Viňa MA, Hollenbach JA, Lyke KE, Sztein MB, Maiers M, Klitz W, Cano P, Mack S, Single R, Brautbar C, Israel S, Raimondi E, Khoriaty E, Inati A, Andreani M, Testi M, Moraes ME, Thomson G, Stastny P, Cao K. Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations (review). Philos Trans R Soc Lond B Biol Sci 367(1590):820-829, 2012. e-Pub 2012. PMID: 22312049.
Jordan SC, Reinsmoen N, Lai CH, Cao, K, Kahwaji J, Peng A, Villicana R, Vo A. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Transplant Proc 44(1):60-61, 2012. e-Pub 2012. PMID: 22310579.
Yanagida R, Czer LS, Reinsmoen NL, Cao, K, Rafiei M, De Robertis MA, Mirocha J, Kass RM, Kobashigawa JA, Trento A. Impact of virtual cross match on waiting times for heart transplantation. Ann Thorac Surg 92(6):2104-2111, 2011. e-Pub 2011. PMID: 22115224.
Cao, K, Street J, Johnson J, Wang Q, Lau M, Darke C. A new HLA-C allele, C*08:43, identified during a UCLA Immunogenetics Centre cell exchange. Tissue Antigens 78(6):459-460, 2011. e-Pub 2011. PMID: 21749330.
Lai CH, Cao, K, Ong G, Naim M, Wang Q, Mirocha J, Vo A, Jordan SC, Reinsmoen NL. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 92(1):48-53, 2011. e-Pub 2011. PMID: 21562450.
Lyke KE, Fernandez-Vina MA, Cao, K, Hollenbach J, Coulibaly D, Kone AK, Guindo A, Birdett LA, Hartzman RJ, Wahl AR, Hilderbrand WH, Doumbo OK, Plowe CV, Sztein MB. Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens 77(6):562-571, 2011. e-Pub 2011. PMID: 21447146.
Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao, K, Lai CH, Villicana R, Peng A, Jordan S, Vo A. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Neph 6(12):2894-2900, 2011. e-Pub 2011. PMID: 22157713.
Reinsmoen NL, Lai CH, Heidecke H, Cao, K, Ong G, Naim M, Wang Q, Mirocha J, Vo AA, Jordan SC, Dragun D. Anti-angiotensin type 1 receptor (AT1R) antibody associated with C4d+ antibody mediated rejection (AMR) in patients with no donor HLA specific antibody (DHSA). Transplantation 90(12):1473-1477, 2010. e-Pub 2010. PMID: 21030904.
Vo AA, Peng A, Toyoda M, Kahwaji J, Cao, K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89(9):1095-1102, 2010. e-Pub 2010. PMID: 20110854.
Jordan SC, Reinsmoen N, Peng A, Lai CH, Cao, K, Villicana R, Toyoda M, Kahwaji J, Vo AA. Advances in diagnosing and managing antibody-mediated rejection (review). Pediatr Nephrology 55(10):2035-2048, 2010. e-Pub 2010. PMID: 20077121.
Street J, Johnson J, Pepperall J, Cao, K, Darke C. A new HLA-DRB1 allele: DRB1*0343. Tissue Antigens 76(3):255-256, 2010. e-Pub 2010. PMID: 20492593.
Mack SJ, Tu B, Lazaro A, Yang R, Lancaster AK, Cao, K, Ng J, Hurley CK. HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 73(1):17-32, 2009. e-Pub 2009. PMID: 19000140.
Leffell MS, Cao, K, Coppage M, Hansen LA, Hart JM, Pereira N, Pereira S, Reinsmoen NL, Senitzer D, Smith A, Torres M, Vega1 R, Fuchs E. Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. Tissue Antigens 74(6):494-498, 2009. e-Pub 2009. PMID: 19804563.
Reinsmoen NL, Lai CH, Vo A, Cao, K, Ong G, Naim M, Wang Q, Jordan SC. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86(6):820-825, 2008. e-Pub 2008. PMID: 18813107.
Lazaro AM, Xiao Y, Cao, K, Masaberg C, Nichol L, Ng J, Hurley CK, Posch PE. Twenty-three novel alleles increase diversity at the HLA-C locus. Tissue Antigens 71(6):560-633, 2008. e-Pub 2008. PMID: 18380775.
Lazaro AM, Xiao Y, Cao, K, Masaberg C, Nichol L, Ng J, Hurley CK, Posch PE. Expanding diversity at the HLA-B locus: 28 novel HLA-B alleles. Tissue Antigens 71(5):471-4, 2008. e-Pub 2008. PMID: 18331525.
Lazaro AM, Xiao Y, Cao, K, Masaberg C, Nichol L, Ng J, Hurley CK, Posch PE. Thirty-two novel HLA-A alleles identified during intermediate resolution testing. Tissue Antigens 71(2):165-8, 2008. e-Pub 2008. PMID: 18069934.
Tu B, Mack SJ, Lazaro A, Lancaster A, Thomson G, Cao, K, Chen M, Ling G, Hartzman RJ, Ng J, Hurley CK. HLA-A, -B, -C, -DRB1 allele and haplotype frequencies in an African American population. Tissue Antigens 69(1):73-85, 2007. e-Pub 2007. PMID: 17212710.
Hou L, Tu B, Ling G, Tang T, Cao, K, Steiner NK, Lazaro A, Ng J, Hartzman RJ, Hurley CK. Strategies for evaluating B*18 allelic diversity by sequence-based typing applied to studies of a population from Singapore and African-Americans. Tissue Antigens 67(1):66-69, 2006. e-Pub 2006. PMID: 16451205.
Lazaro AM, Cao, K, Masaberg C, Steiner NK, Xiao Y, Tu B, Turner V, Nickerson P, Stoll S, Schall C, Valdez R, Ng J, Hartzman RJ, Hurley CK. Twenty-three novel HLA-B alleles identified during intermediate-resolution testing. Tissue Antigens 68(3):245-248, 2006. e-Pub 2006. PMID: 16948646.
Lazaro AM, Steiner NK, Cao, K, Slack R, Chen DS, Xiao Y, Beduhn E, Ng J, Hartzman RJ, Hurley CK. Searching for HLA-DRB1*1206 in volunteer marrow donors in four US population groups. Tissue Antigens 68(5):439-441, 2006. e-Pub 2006. PMID: 17092258.
Helms C, Saccone NL, Cao L, Daw JA, Cao, K, Hsu TM, Taillon-Miller P, Duan S, Gordon D, Pierce B, Ott J, Rice J, Fernandez-Vina MA, Kwok PY, Menter A, Bowcock AM. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118(3-4):466-76, 2005. e-Pub 2005. PMID: 16235096.
S-X H, Y-B S, J-H L, Gneg, Zhai N, Cao, K, F-J S. High resolution DNA typing for HLA-A, B, Cw genes by polymerase chain reaction-sequence specific oligonucleotide probes method in the Shenyang Ban population. Chinese Journal of Medical Genetics 22(6):665-667, 2005. e-Pub 2005. PMID: 16331567.
Cao, K, Moormann AM, Lyke KE, Masaberg C, Sumba OP, Doumbo OK, Koech D, Lancaster A, Nelson M, Meyer D, Single R, Hartzman RJ, Plowe CV, Kazura J, Mann DL, Sztein MB, Thomson G, Fernández-Viña MA. Differentiation between African populations is evidenced by the diversity of Alleles and Haplotypes of HLA class I Loci. Tissue Antigens 63(4):293-325, 2004. e-Pub 2004. PMID: 15009803.
Burdett, LA, Cao, K, Zhang, GH, Fernandez-Vina, M. Twenty-eight novel HLA class I alleles. European Journal of Immunogenetics 28(2):342, 2001. e-Pub 2001.
Demarest JF, Jack N, Cleghorn FR, Greenberg ML, Hoffman TL, Ottinger JS, Fantry L, Edwards J, O'Brien TR, Cao K, Mahabir B, Blattner WA, Bartholomew C, Weinhold KJ. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 17(14):1333-1344, 2001. e-Pub 2001. PMID: 11602044.
Ellexson-Turner ME, Leffell MS, Zachary AA, Turner S, Bennett T, Sidebottom DA, Cao K, Fernández-Viña MA, Hildebrand WH. Sequence-Based Typing of HLA-Class I Alleles in Alaskan Yupik Eskimo. Human Immunology 62(6):639-644, 2001. e-Pub 2001. PMID: 11390039.
Hollenbach JA, Thomson G, Fernández-Viña MA, Cao, K, Erlich HA, Bugawan T, Winkler C, Klitz W. HLA diversity, differentiation and haplotype evolution in mesoamerican natives. Hum Immunology 62(4):378-390, 2001. e-Pub 2001. PMID: 11295471.
Bowcock AM, Shannon W, Du FH, Duncan J, Cao, K, Aftergut K, Catier J, Fernández-Viña MA, Menter A. Insights into psoriasis and other inflammatory diseases from large scale gene expression studies. Hum Mol Gent 10(17):1793-1805, 2001. e-Pub 2001. PMID: 11532989.
Cao, K, Hollenback J, Shi X, Shi W, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Human Immunology 62(9):1009-1030, 2001. e-Pub 2001. PMID: 11543903.
Yu N, Ohashi M, Salazar M, Cao, K, Fernández-Viña MA, Yunis EJ. Typing of HLA-B*15 alleles using sequence-specific primers. Tissue Antigens 52(3):260-269, 1998. e-Pub 1998. PMID: 9802606.
Mann DL, Garner R, Dayhoff DE, Cao, K, Fernández-Viña MA, Birx DL, Michael NL. Major histocompatibility complex genotype is associated with disease progression and viral load levels in a cohort of HIV-1 infected Caucasians and African-Americans. J Infect D 178(6):1799-1802, 1998. e-Pub 1998. PMID: 9815238.
Cao, K, Song FJ, Li HG, Xu SY, Liu ZH, Su XH, Wang FX. Association between HLA antigens and families with psoriasis vulgaris. Chin Med J. (Engl) 106(2):132-135, 1993. e-Pub 1993. PMID: 8504697.
Xu SY, Song FJ, Dong XP, O GC, Li HG, Cao, K, Xiao Y, Wang FX. HLA antigens and polyposis of gall bladder. Chinese Medical Genetics J 10(3):135-137, 1993. e-Pub 1993.
Cao, K, Song FJ, Li HG, Xu SY, Xiao Y, Su XH, Wang FX. HLA antigens and herpes zoster. Chinese Dermatology J 25(5):316-318, 1992. e-Pub 1992.
Xu SY, Song FJ, Cao, K, Xiao Y, Li HG, Wang FX, He WD, O GC, Tong XP. Family study on association between polyposis of gall bladder and HLA antigens. Chinese Immunology J 8(5):295-297, 1992. e-Pub 1992.
Xiao Y, Song FJ, Li HG, Xu SY, Cao, K, Su XH, Wang FX. Study on association between HLA antigens and pustular psoriasis palmaris and plantaris. Chinese Dermatology J 25(4):262-263, 1992. e-Pub 1992.
Cao, K, Song FJ, Li HG, Xu SY, Liu ZH, Su XH, Wang FX. Association between HLA Antigens and Families with psoriasis vulgaris. Chinese Dermatology J 23(6):381-383, 1990. e-Pub 1990.
Cao, K. Report of a case with granuloma on the skin. Chinese Dermatology J 21(4):205-207, 1988. e-Pub 1988.
Cao, K. Report on manifestation on the skin of three cases with hemophilia. Chinese Dermatology J 19(4):232-233, 1986. e-Pub 1986.

Invited Articles

Kongtim P, Cao K, Ciurea SO. Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation. Review Article - Advances in Hematology 2016 (2016), 2016. e-Pub 2016. PMID: 26904122.
Cao K, Chopek M, Fernández-Viña MA. High and intermediate resolution DNA typing systems for class I HLA-A, B, C genes by hybridization with sequence-specific oligonucleotide probes (SSOP). Reviews in Immunogenetics 1(2):177-208, 1999. e-Pub 1999. PMID: 11253946.

Abstracts

Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 140(Supplement 1):4880-4881, 2022. e-Pub 2022.
Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 140(Supplement):10530-10531, 2022. e-Pub 2022.
Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao AK. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with PTCy Prophylaxis. Blood 140(Supplement 1):7649-7650, 2022. e-Pub 2022.
Saliba RM, Greenbaum U, Ma Q, Srour SA, Rondon G Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. Blood 138(Supplement 1):1804, 2021. e-Pub 2021.
Ciurea SO, Schafer J, Kongtim P, Chen J, Soebbing D, Cao K, Srour SA, Shpall EJ, Konopleva M, Lee DA, Champlin RE. Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. Blood 136(Supplement 1):11-12, 2020. e-Pub 2020.
Ciurea SO, Bassett R, Soebbing D, Rondon G, Cao K, Olson AL, Bashir Q, Shpall EJ, Devine S, Pasquini MC, Martin AS, Lee DA, Champlin RE. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood 134(Supplement 1):700, 2019. e-Pub 2019.
Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(Supplement 1):47, 2019. e-Pub 2019.
Zou J, Barnes T, Lopez A, Pardillo W, Haneke R, Guerrero E, Cao K. The complement interference effect in HLA antibody detection in hematopoietic stem cell transplant patients: A validation study of EDTA treatment in labscreen PRA and single antigen assay. Human Immunology 78 (2017)(Supplement 1):207 (P204), 2017. e-Pub 2017.
Zou J, Willis D, Moore B, Carmazzi Y, Cao K. KIR matching and KIR haplotype frequencies in hematopoietic stem cell transplant (HSCT) Patients and HLA matched related donors. Human Immunology 78 (2017)(Supplement 1):206 (P202), 2017. e-Pub 2017.
Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation S1083-8791(17):30449-4, 2017. e-Pub 2017. PMID: 28506845.
Patel H, CarmazziY, Barnes T, Cano P, Fernandez-Vina M, Cao K. Frequencies of Recombination in the HLA Class I and II Regions in Hematopoietic Stem Cell Transplant Patients and Related Donors. Human Immunology 77 (2016)(Supplement 1 (P115)):122, 2016. e-Pub 2016.
Guerrero E, Smith N, Cao K. The Quest for Resolving a Mystery. Human Immunology 77 (2016)(Supplement 1):150 (P154), 2016. e-Pub 2016.
Smith NT, Ngo V, Carmazzi Y, Krishnakumar S, Li M, Wang C, Guerrero E, Mindrinos M, Cao K. Next Generation Sequencing of all Classical HLA-Class I and II Genes. Human Immunology 77 (2016)(Supplement 1):90 (P073), 2016. e-Pub 2016.
Shah N, Li L, McCarty J, Kaur I, Yvon E, Orlowski RZ, Cooper L, Parmar S, Cao K, Hosing C, Ahmed S, Nieto Y, Patel KK, Bashir Q, Kent S, Bollard C, Champlin RE, Rezvani K, Shpall EJ. Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma. Journal of Clinical Oncology 34 (2016)(15 (May 20 Supplement 2016) TPS3100), 2016. e-Pub 2016.
Cano P, Cao K, Garcia-Gomez J, Gendzekhadze K. Selective Pressure On HLA Haplotypes To Maximise Interaction With Natural Killer Cells. Human Immunology 76(Supplement 1 (Oral)):36, 2015. e-Pub 2015.
Cao K, Zhao W, Smith N, Carmazzi Y, Shpall E, Rezvani K. Characterization of Copy Number Variations (CNV) In the NKG2C Receptor Gene. Human Immunology 76 (2015)(Supplement 1 (0198-8859)):135, 2015. e-Pub 2015.
Moore B, Zhao W, Willis D, Lopez A, Liao S, Barnes T, Hoang H, Ngo V, Hamm W, Mai V, Wang Q, Guerrero E, Cao K. Identification of Eleven Novel HLA Alleles by Sequence Based Typing (SBT): A*02:557, A*11:01:64, B*40:299, B*53:37, C*01:98 N, C*02:14:02, C*04:195, C*08:110, C*08:111, DRB1*03:110, DRB*13:184. Human Immunology 76 (2015)(Supplement 1 (0198-8859)):102, 2015. e-Pub 2015.
Saltarrelli J, Willis D, Rezvani K, Cao K. Copy Number Variation (CNV) of Kir Genes Characterized Using QRT-PCR Technique. Human Immunology 76 (2015)(Supplement 1 (0198-8859)):111, 2015. e-Pub 2015.
Ciurea SO, Kongtim P, Popat U, Aung F, Champlin RE, Cao K. Complement-binding Donor-specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. 20th Congress of the European Hematology Association, 2015 100 (2015)(s1):278, 2015. e-Pub 2015.
Baljevic M, Cao K, Champlin RE, Hosing C, Shah N, Parmar S, Rezvani K, Olson AL, Shpall EJ, Oran B. Use of dual donor T-cell chimerism to predict prognosis after double cord blood allogeneic transplantation. Journal of Clinical Oncology 33 (2015)(15 Supplement), 2015. e-Pub 2015.
Sekine T, Marin D, Cao K, Sobieski C, Rondon G, Shaim H, Alsuliman A, Oran B, Hosing C, Kondo K, Muftuoglu M, Popat UR, Jones RB, Andersson BS, Kebriaei P, Nieto Y, Shah ND, Sarvaria A, Alousi AM, Parmar S, Champlin R, Shpall EJ, Rezvani K. HLA and KIR Genomics to Determine Outcome After Cord Blood Transplant (CBT). NK2015 15th Meeting of the Society for Natural Immunity, 2015. e-Pub 2015.
Gaballa S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, AL-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash MH, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood 126 (2015)(23), 2015. e-Pub 2015.
Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi AM, Hosing C, Popat UR, Kebriaei P, Champlin RE, McNiece IK, De Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. Blood 126 (2015)(23), 2015. e-Pub 2015.
Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski R, Cooper LJN, Lee D, Parmar S, Caoi K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. Blood 126 (2015)(23), 2015. e-Pub 2015.
Ciurea SO, Lee DA, Cao K, Rondon G, Chen J, Willis DB, Ahmed S, Yvon E, Rezvani K, Shpall E, Champlin RE. Phase 1 Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias. Blood 126 (2015)(23), 2015. e-Pub 2015.
Oran B, Saliba RM, Carmazzi Y, Shpall EJ, Rezvani K, De Lima M, Fernandez-Vina M, Champlin RE, Cao K. Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index. Blood 126 (2015)(23), 2015. e-Pub 2015.
Baljevic M, Cao K, Champlin RE, Hosing C, Shah N, Parmar S, Rezvani K, Olson A, Shpall EJ, Betul O. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. Biology of Blood and Marrow Transplantation 21 (2015)(2, Supplement 1):S157, 2015. e-Pub 2015.
Zhao W, Guerrero E, Willis D, Cao K. HLA gene mutagenesis caused by tumor blast cells in peripheral blood. Human Immunology 75(Supl 1):88, 2014. e-Pub 2014.
Zhao W, Moore BS, Guerrero E, Partlow D, Cao K. Identification of novel HLA alleles by sequence based typing (SBT): A*33:73N and C*03:218. Human Immunology 75(Supl 1):87, 2014. e-Pub 2014.
Oran B, Cao K, Saliba RM, Hosing C, Popat UR, deLima M, Alousi AM, Kebriaei P, Nieto Y, Rondon G, Shah N, Parmar S, Champlin, RE, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 124(21 (2014)), 2014. e-Pub 2014.
Cao K, Carmazzi Y, Shpall E, Guerrero E, Barnes T, Moore B, Willis D, Hosing C, Oran B, Sadeghi T, Ngo V, Artigas AT, Armitage S, Fernández-Viña M, Rezvani K. Distribution of KIR HLA ligands in transplant patients and their cord blood unit (CBU) donors. Human Immunology 75(Supl 1):89, 2014. e-Pub 2014.
Moore B, Guerrero E, Carmazzi Y, Cao K. Frequency of HLA-B*44:03-C*04:09N bearing haplotypes and phenotypes in leukemia patients. Human Immunology 75(Supl 1):16, 2014. e-Pub 2014.
Reinsmoen JL, C-H L, Mirocha J, Cao K, Naim M, Ong GD, Wang Q, Guong H, Riega S, Rafiei M, Patel J, Kobashigawa J. Anti-Angiotensin Type 1 Receptor Antibodies Associated With Rejection in Donor HLA Antibody Negative Recipients. Am J Transplant 13(5):456, 2013. e-Pub 2013.
Cao K, Fernández-Viña M, Barnes T, Carmazzi Y, Patel H, Partlow D, Cano P, Champlin R, Ciurea SO. Levels of Anti-HLA Donor Specific Antibodies (DSA) and Graft Outcome in Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 19(2 (Supplement 2)):S344, 2013. e-Pub 2013.
Reinsmoen NL, C-H L, Mirocha J, Cao K, Ong GD, Naim M, Wang Q, Riega S, Rafiei M, Patel J, Kobashigawa J. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies Together with de novo Donor HLA Specific Antibodies on Grant Outcome in Heart Transplant Recipients. J Heart and Lung Trasplant 32(4):S113, 2013. e-Pub 2013.
Cao K, Guerrero E, Carmazzi Y, Barnes T, Cano P, Rezvani K, Shpall E, Fernández-Viña M. Diversify HLA-ligands (HLA-L) for killer cell immunoglobulin-like receptor (KIR) genes in umbilical cord blood units (UCBU) could benefit patients (PTS) in need of hematophoietic stem cells (HSC) transplants (Tx). Human Immunology 74(51):25, 2013. e-Pub 2013.
Amir H, Fernández-Viña MA, Aung F, Poon LM, Kornblau S, Cao K, Champlin RE, Ciurea SO. Changes in HLA Antigens Is Not a Major Mechanism of Acute Myeoid Leukemia Relapse After Matched Allogeneic Stem Cell Transplantation. Biol Blood and Marrow Transplantation 19(2 (Supplement 2)):S116, 2013. e-Pub 2013.
Cano P, Patel H, Cao K. Anti HLA-Class-I antibodies an platelet transfusion refractoriness. Hman Immunology 74(51):169, 2013. e-Pub 2013.
Zhao W, Guerrero E, Willis D, Barnes T, Carmazzi Y, Partlow D, Cano P, Cao K. Identification of novel HLA alleles by sequence based typing (SBT): A*01:114, A*02:397, A*11:129, A*32:46, B*44:160 and C*07:307. Human Immunology 74(51):141, 2013. e-Pub 2013.
Cao K, Guerrero E, Zhao W, Willis D, Barnes T, Smith N, Liao S, Moul D, Partlow D, Cano P, Fernandez-Vina, MA. Identification of New HLA Alleles by Sequence Based Typing: B*40:206, C*20:58, DQB1*03:40, DQB1*6:50. Human Immunology 73(1):107, 2012. e-Pub 2012.
Cao K, Lai CH, Flores SV, Rafiei M, Mirocha J, Haas M, Ong G, Naim M, Wang Q, Constanza L, Patel J, NL Reinsmoen NL, Kobasigawa J. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complication in Heart Transplant. Heart and Lung Transplantation 31(4S):S163, 2012. e-Pub 2012.
Cao K, Lai CH, Flores SV, Rafiei M, Mirocha J, Hass M, Ong G, Naim M, Wang Q, Constanza L, Patel P, Reinsmoen NL, Kobashigawa J. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) identify Patients at Risk for Immune Complication in Heart Transplant. Supplemental to the Journal of Heart and Lung Transplantation 31(4S):463, 2012. e-Pub 2012.
Vo AA, Choi J, KahwajuJ, Cisneros K, Peng A, Villicana R, Reinsmoen N, Lai CH, Cao K, Jordan SC. Analysis of Factors Associated with Risk for Antibody-Mediated Rejection in Broadly Sensitized Patients Desensitized for Deceased Donor (DD) Transplantation. Am J Transpl 12(S3(12)):414, 2012. e-Pub 2012.
Vo AA, Choi J, Kahwaji J, Cisneros K, Peng A, Villicana R, Reinsmoen M, Lai CH, Cao K, Jordan SC. Analysis of Factors Associated with Unresponsiveness to Densitization Using IVIG and Rituximab in Broadly HLA Sensitized Patients. Amer J Transp 12(Sup 3(12)):233, Abstract #691, 2012. e-Pub 2012.
Cao K, C-H L, Vo AA, Mirocha J, Naim M, Ong G, Maskawa R, Duong H, Wang Q, Jordan SC, Reinsmoen NL. High CPRA is associated with earlier occurrence of AMR in kidney transplant patients. Visuals of the Clinical Histocompatibility Workshop, March 2011, Punta Cana, DR:28, 2011. e-Pub 2011.
Cao K, Lai CH, Ong G, Naim M, Wang Q, Kobashigawa J, Reinsmoen NL. Role of Anti-HLA antibody assessment and risk stratification in heart transplantation. Human Immunol 72(Suppl 1):S1, 2011. e-Pub 2011.
Cao K, Wang Q, Naim M, Lai CH, Ong G, Reinsmoen NL. Identification of a novel DRB1*08:01 haplotype carrying DRB3*01:01 by molecular methods. Human Immunol 72(Suppl 1):S5, 2011. e-Pub 2011.
Lai CH, Masukawa R, Paredes DV, Ong G, Wang Q, Naim M, Cao K, Kobashigawa J, Reinsmoen NL. C4d+ antibody mediated rejection in absence of complement fixing donor specific antibody for a heart transplant patient. Human Immunol 72(Suppl 1):S90, 2011. e-Pub 2011.
Lai CH, Cao K Ong G, Naim M, Wang Q, Haas M, Kahwaji JM, Peng A, Villicana R, Vo AA, Jordan SC, Reinsmoen NL. Antibody testing strategies for selection of deceased donors (DD) for broadly sensitized patients following pretransplant immunomodulatory therapy. Amer J Transplant 11(Suppl 2):472, 2011. e-Pub 2011.
Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Lai CH, Cao K, Villicana R, Peng A, Jordan S, Vo A. Infectious outcomes in kidney transplant recipients treated with IVIG and Rituximab (IVIG+RIT) for desensitization versus non-rituximab treated recipients. Amer J Transplant 11(Suppl 2):322, 2011. e-Pub 2011.
Ghandehari S, Falk JA, Chaux G, Simsir S, Chang W, Lai CH, Cao K, Reinsmoen N. Unique Approach for Identifying Compatible Donors for Lung Transplant Recipients with HLA Specific Antibodies Using the Virtual Crossmatch and Desensitization. Supplemental to the Journal of Heart and Lung Transplantation, 2010. e-Pub 2010.
Chih-Hung Lai C, Ong G, Nail M, Cao K, Vo AA, Jordan SC, Reinsmoen NL. Tracking impact of IVIG and Rituximab combination therapy on HLA antibody specificities and strengths. AmeR J Transplant 10(Suppl 4):420-21, 2010. e-Pub 2010.
Ge S, Pao A, Reinsmoen N, Vo AA, C-H L, Deer N, Karasyov A, Peng A, Cao K, Aguiluz A, Villlicana R, Wang Q, Jordan SC, Toyoda M. Monitoring highly sensitized patients (HS) post-transplant (Tx) by intracellular cytokine flow cytometry (CFC) together with donor specific antibody (DSA) predicts risk of antibody mediated rejection (AMR) and allograft dysfunction. Amer J Transplant 10(Suppl 4):220, 2010. e-Pub 2010.
Lai CH, Okhovat J, Ong G, Wang Q, Naim M, Cao K, Reinsmoen NL. Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay. Human Immunol 71(Suppl. 1):S62, 2010. e-Pub 2010.
Cao K, Wang Q, C-H L, Naim M, Ong G, Duong H, Semendyayeva M, Reinsmoen N. Identification of novel HLA alleles of A*9241, B*9546, B*350107 and Cw*0763 by sequence-based typing (SBT). Human Immunol 70(Suppl. 1):S80, 2009. e-Pub 2009.
Cao K, Coleman B, Czer LS, Simsir S, Schwarz E, C-H L, Ong G, Wang Q, Naim M, Reinsmoen NL. No Significant Impact of HLA Specific Antibodies (Ab) and Donor Specific Antibodies (DSA) on Heart Transplant Outcome Subsequent to Thymoglobulin Induction. Supplemental to the Journal of Heart and Lung Transplantation 28(25):s260, 2009. e-Pub 2009.
Colovos C, Coleman B, Reinsmoen N, Cao K, C-H L, Czer L, Schwarz ER, Simsir SA. Virtual Crossmatch in Heart Transplantation. Supplemental to the Journal of Heart and Lung Transplantation 28(25):s88, 2009. e-Pub 2009.
Toyoda M, Ge S, Pao A, Lai, C-H, Vo A, Wang Q, Pichurin P, Ong G, Deer N, Cao K, Aguiluz A, Karasyov A, Reinsmoen N, Jordan SC. Cellular Allo-Reactivity against Paternal HLA (PHLA) Antigens (AGS) in Multiparous Normal Females (NF) as Detected by Intracellular Cytokine Flow Cytometry (CFC) Remains Elevated over Years Despite Diminution of Anti-HLA Antibody (AB) Levels, Suggesting Allo-AG Specific Memory Cell Activity. American J Transplantation Supplement 2(9):214, 2009. e-Pub 2009.
Vo AA, Cao K, C-H L, Reinsmoen N, Toyoda M, Ge S, Peng A, Villicana R, Jordan SJ. Characteristics of Patients Who Developed Antibody Mediated Rejection (AMR) Post-Transplant after Desensitization with IVIG + Rituximab: Analysis of Risk Factors & Outcomes. American J Transplantation Supplement 2(8):334, 2009. e-Pub 2009.
C-H L, Ong G, Naim M, Cao K, Vo AA, Jordan SC, Reinsmoen NL. Paradigm for Predicting Risk of Antibody Mediated Rejection After Desensitization. American J Transplantation Supplement 2(8):416, 2009. e-Pub 2009.
Cao K, Vo A, C-H L, Wang Q, Ong G, Naim M, Jordan S, Reinsmoen NL. HLA Mismatching Has No Significant Impact on Kidney Transplant Outcomes of Highly HLA Sensitized Patients with IVIG +/- Rituximab. American J Transplantation Supplement 2(8):546, 2009. e-Pub 2009.
Vo AA, Cao K, C-H L, Reinsmoen N, Toyoda M, Ge S, Peng A, Villicana R, Jordan SC. Long Term Outcome in Highly HLA Sensitized (HS) Patients Receiving Desensitization with IVIG and Single-dose (SD) Rituximab. American J Transplantation Supplement 2(9):557, 2009. e-Pub 2009.
C-H L, Vo A, Cao K, Jordan SC, Reinsmoen NL. Immunological Selection Criteria Identifying Patients for Successful Desensitization (DES) with IVIG and Rituxan. American J Transplantation Supplement 2(8):558, 2009. e-Pub 2009.
Ge S, Pao A, Reinsmoen N, Vo A, C-H L, Deer N, Peng A, Cao K, Aguiluz A, Villicana R, Wang Q, Karasyov A, Jordan SC, Toyoda M. Monitoring Highly Sensitized Patients (HS) Post-Transplant (TX) by Intracellular Cytokine Flow Cytometry (CFC) Together with Donor Specific Antibody (DSA) and Pre-desensitization (PRE-DES) B Cell Crossmatch (B-CMX) Predicts Risk of Antibody Mediated Rejection (AMR). American J Transplantation Supplement 2(9):560, 2009. e-Pub 2009.
Vo AA, Toyoda M, Ge S, C-H L, Cao K, Reinsmoen N, Peng A, Villicana R, Jordan SC. Long Term Outcomes of Deceased Donor (DD) Transplants in Highly HLA Sensitized Patients (HS) Desensitized with IVIG and Single-dose (SD) Rituximab. American J Transplantation Supplement 2(9):561, 2009. e-Pub 2009.
Reinsmoen NL, Cao K, C-H L, Coleman B, Czer LSC, Simsir S, Vo AA, Jordan SC. Improving Organ Allocation for Highly Sensitized (HS) Heart (HT) and Kidney (KID) Recipients: Defining Criteria for Unacceptable Antigen (UA) Assignment Using a Calculated PRA (CPRA) and Flow Crossmatch (FXM) Trajectory. American J Transplantation Supplement 2(9):645, 2009. e-Pub 2009.
C-H L, Okhovat J, Ong G, Wang Q, Naim M, Cao K, Reinsmoen N. Standardizing Luminex platform readers. Human Immunol 70(Suppl. 1):S29, 2009. e-Pub 2009.
Reinsmoen NL, Dragun D, C-H L, Cao K, Vo A, Jordan S. Humoral responses to a non-HLA specific antigen. Angiotensin type I receptor (AT1R) are associated with early antibody mediated acute rejection (AMR). Human Immunol 70(Suppl. 1):S108, 2009. e-Pub 2009.
C-H L, Ong G, Wang Q, Naim M, Cao K, Vo AA, Jordan SC, Reinsmoen NL. Identifying the optimal windows for transplantation through active surveillance of antibody levels after desensitization. Human Immunol 70(Suppl. 1):S165, 2009. e-Pub 2009.
Simsir SA, Czer LS, Schwarz ER, Kass RM, Mirocha J, Coleman B, Cao K, Reinsmoen N. Virtual Crossmatching by Flow Cytometry and Luminex Expands the Donor Pool and Potentially Shortens the Wait Time in Heart Transplant Candidates with Panel Reactive Antibody. American Heart Association, 2009. e-Pub 2009.
Czer LSC, Coleman B, Simsir SA, Schwarz ER, C-H L, Cao K, Jordan S, Osmen A, Jamero G, Phan A, Rafiei M, Reinsmoen N. Desensitization of Highly HLA-Sensitized Heart Transplant Candidates Using High-Dose Intravenous Immunoglobulin and Rituximab with Successful Transplantation. American College of Cardiology, 2009. e-Pub 2009.
Chen DF, Cao K, Balsara KR, Burgess B, Palmer S, Davis RD, Reinsmoen NL. Impact of Desensitization Therapies for Third Party HLA Specific Antibodies on Lung Transplant Outcomes. American J Transplantation Supplement 2(8):546, 2008. e-Pub 2008.
Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Jordan SC. Successful Deceased and Living Donor Kidney Transplantation after Desensitization Therapy in the Presence of Donor Specific Antibodies (DSA): Determination of Acceptable Pre- and Posttransplant DSA Levels, 2008. e-Pub 2008.
Cao K, Ong G, Lai CH, Wang Q, Naim M, Lill M, Reinsmoen NL. Impact of HLA Antibody on Mismatched Hematopoietic Stem Cell Transplants (HSCT) Outcome. 15th International Histocompatibility and Immunogenetics Workshop, 2008. e-Pub 2008.
Lai CH, Ong G, Naim M, Cao K, Vo A, Jordan SC, Reinsmoen NL. Different Induction Protocol Effects on Renal Transplant Patients Donor Specific Antibodies (DSA) with High Dose IVIg+Rituxan Desensitization Treatment. American Society for Histocompatibility and Immunogenetics. Human Immunology 69(S1):S28, 2008. e-Pub 2008.
Cao K, Lai CH, Vo A, Ong G, Naim M, Wang Q, Jordan SC, Reinsmoen NL. Detection of Acceptable Donor Specific Anti-HLA Antibodies (DSA) Levels Permissive for Deceased and Living Donor Kidney Transplantation (TX) after Desensitization Therapy. Human Immunology 69(S1):S9, 2008. e-Pub 2008.
Toyoda M, Pao A, Ge S, Vo A, Lai CH, Lukovsky M, Wang Q, Radha R, Ong G, Sado T, Cao K, Baden L, Petrosyan A, Skinner E, Reinsmoen NL, Jordan SC. Elevated Allo-Reactivity in Normal Multiparous Females as Detected by Intracellular Cytokine Flow Cytometry (CFC) is Directed against Paternal HLA Antigens (AGs) and May Impact Risk for Antibody Mediated Rejection (AMR) if Transplanted. American J Transplantation Supplement 2(8):509-10, 2008. e-Pub 2008.
Lazaro AM, Steiner N, Cao K, Slack R, Chen S, Xiao Y, Beduhn E, Ng J, Hartzman RJ, Hurley CK. Seeking DRB1*1206 in Four U.S. Populations. Human Immunology 67(S1):S157, 2006. e-Pub 2006.
Tu B, Ling GY, Tang T, Cao K, Montemayor C, Hartzman RJ, Ng J, Hurley CK. Using sequence based typing to define HLA-A, B, C, DRB1 alleles in 564 African Americans. Human Immunology 66(S1):S53, 2005. e-Pub 2005.
Lazaro AM, Cao K, Masaberg C, Steiner N, Tu B, Ng J, Hartzman RJ, Hurley CK. The discovery of new HLA alleles: what kinds of variants are being detected today. Human Immunology S1(S46), 2005. e-Pub 2005.
Cao K, Lyke KE, Masaberg C, Doumbo OK, Ng J, Hartzman RJ, Plowe CV, Sztein MB, Fernandez-Vina MA. HLA-A, -B and -Cw allele frequencies in a population from Bandigara, Mali. Human Immunology 65(9-10):1004-1006, 2004. e-Pub 2004.
Moormann AM, Cao K, Masaberg C, Sumba OP, Koech D, Ng J, Hartzman RJ, Kazura J, Fernandez-Vina MA. HLA-A, -B and -Cw allele frequencies in a Nandi population from Kenya. Human Immunology 65(9-10):999-1001, 2004. e-Pub 2004.
Moormann, AM, Cao K, Masaberg C, Sumba OP, Koech D, Ng J, Hartzman RJ, Kazura J, Fernandez-Vina MA. HLA-A, -B and -Cw allele frequencies in a Luo population from Kenya. Human Immunology 65(9-10):997-999, 2004. e-Pub 2004.
Cao K, Masaberg C, Lazaro A, Machan C, Ng J, Hartzman RJ, Fernández-Viña MA. Increased diversity by adding HLA-C typing to HLA-A, -B and DRB testing. Human Immunology 64(S1):99, 2003. e-Pub 2003.
Lazaro A, Burdett L, Cao K, Machan C, Husted LG, Lyke KE, Doumbo OK, Ng J, Hartzman RJ, Plowe CV, Sztein MB, Fernández-Viña MA. HLA-B-Cw-DRB1-DQA1-DQB1 haplotypes diversity in Mali population. Human Immunology 64(S1):135, 2003. e-Pub 2003.
Cao K, Masaberg C, Machan C, Husted LG, Ng J, Hartzman RJ, Hurley CK, Fernandez-Vina MA. Analysis of the Diversity Generated by Typing HLA-A, B Loci by PCR-SSOP of Potential Volunteer Marrow Donors. Human Immunology 63(S1):41, 2002. e-Pub 2002.
Cao K, Lazaro A, Machan C, Husted LG, Ng J, Hartzman RJ, Fernández-Viña MA. HLA-A, -B and DRB Intermediate Resolution Typing (IR) of 20,357 Subjects Reveals an Impressive Degree of HLA Genotype Diversity. Human Immunology 63(S1):45, 2002. e-Pub 2002.
Cao K, Yu J, Masaberg C, Le CT, Erdley M, Ng J, Hartzman RJ, Fernández-Viña MA. DNA Typing of HLA-AB Alleles at Intermediate Resolution Level of 1902 Turkish Population. European J of Immunogenetics:181, 2002. e-Pub 2002.
Cao K, Masaberg C, Yu J, Moorman A, Zimmerman P, Sztein M, Mann D, Fernández-Viña MA. High levels of HLA class I diversity in four African populations as compared to other ethnic groups. European J of Immunogenetics 28(2):278, 2001. e-Pub 2001.
Hollenbach JA, Cao K, Thomson G, Fernández-Viña MA. Phylogenetic analysis of admixed and related population at the class I loci. Human Immunology 62(S1):59, 2001. e-Pub 2001.
Cao K, Masaberg C, Yu J, Moormann A, Zimmerman P, Sztein M, Mann D, Fernández-Viña MA. Gene and haplotype frequencies of HLA class I-A, B, C loci in four African populations. Human Immunology 62(S1):46, 2001. e-Pub 2001.
Burdett L, Cao K, Zhang GH, Fernández-Viña MA. Twenty-eight novel HLA class I alleles. European J of Immunogenetics 28(2):342, 2001. e-Pub 2001.
Cao K, Fernández-Viña MA. HLA class I diversity in outbred North American populations. European J of Immunogenetics 28(2):274, 2001. e-Pub 2001.
Cao K, Masaberg C, Erdley M, Yu J, Leighton-Herrmann B, Fernández-Viña MA. Study of the Associations of HLA-B*7301 with HLA-A and C Alleles. Human Immunology 61(S2):56, 2000. e-Pub 2000.
Bowcock AM, Cao K, Lander S, Barns R, Kuykendall L, Menter A, Fernández-Viña MA. The Contribution of HLA Class I Alleles to Psoriasis in Nuclear and Extended Families. Human Immunology 61(S1):71, 2000. e-Pub 2000.
Fernández-Viña MA, Cao K, Noreen H, Ball EJ, Harper A, Masaberg C, Yu J, Segall M, Ellison MD, Wetszteon P, Ting A, Cook D. HLA Allele Level Matching Using DNA Methods and Its Impact in Graft Outcome of Cadaver Kidney Transplatations with Zero HLA-Antigen Mismatch Shared According to United Network for Organ sharing (UNOS) Policy. Human Immunology 61(S1):49, 2000. e-Pub 2000.
Hollenbach JA, Thomason G, Cao K, Fernández-Viña MA, Bugawan T, Erich HA, Klitz W. Seven-locus Class I and Class II Haplotypes in Three Amerindian Populations. Human Immunology 61(S2):29, 2000. e-Pub 2000.
Gutierrez M, Araujo HA, Cao K, Burdett L, Osowski L, Fernández-Viña MA. Serological Reactivity of Novel HLA-A and B Alleles. Human Immunology 61(S2):34, 2000. e-Pub 2000.
Cao K, Yu J, Masaberg C, Le CT, Fernández-Viña MA. The Rab Marrow Donor Registry. Molecular Typing of HLA-A and B Alleles in the Population from Israel: Distribution of Alleles and Haplotypes. Human Immunology 61(S2):39, 2000. e-Pub 2000.
Cao K, Yu J, Hollenbach JA, Lazaro A, Marcos CY, Burdett L, Moraes ME, Moraes JR, Klitz W, Stastny P, Fernández-Viña MA. DNA Typing of HLA-A, B, C Alleles in Amerindian Populations by PCR-SSOP. Human Immunology 60(S1):110, 1999. e-Pub 1999.
Burdett L, Cao K, Zhang GH, Hewavitharana TY, Fernández-Viña MA. Novel Alleles Identified in HLA-A, B and C loci. Human Immunology 60(S2):57, 1999. e-Pub 1999.
Ellexson-Turner M, Turner S, Bennett T, Cao K, Fernández-Viña MA, Zachary A, Leffell S, Hildebrand WH. Detection of New Class I Alleles in Alaskan Yupik Eskimo. Human Immunology 60(S2):53, 1999. e-Pub 1999.
Cao K, Yu J, Le CT, Assia M, Masaberg C, Leighton-Herrmann B, Schumacher S, Hummler A, Rutt C, Fernández-Viña MA. Intermediate Resolution Molecular Typing of HLA-A, B Alleles for 3,027 Germany Registry Donors by PCR-SSOP. Human Immunology 60(S2):45, 1999. e-Pub 1999.
Burdett L, Cao K, Zhang GH, Hewaithara T, Fernández-Viña MA. Novel Alleles of the HLA Loci. Human Immunology 60(S1):41, 1999. e-Pub 1999.
Cao K, Noreen H, Masaberg C, Yu J, Segall M, Pearson T, Cook D, Ellison MD, Wetszteon P, Ting A, Fernández-Viña MA. Molecular Typing of HLA-A, B, C, DRB1 Genes for Kidney Transplantation Donor-recipient Pairs of the United Network Organ Sharing (UNOS) Program by PCR-SSOP. Human Immunology 60(S2):24, 1999. e-Pub 1999.
Cao K, Carter C, Yu J, Le T, Assia M, Hunter J, Fernández-Viña MA. DNA Typing of HLA-Bw4/Bw6 Related Alleles by Group-specific Amplifications and SSOP. Human Immunology 59(S1):12, 1998. e-Pub 1998.
Cao K, Shi XJ, Shi WX, Burdett L, Hunter J, Chopek M, Fernández-Viña MA. Analysis of the linkage disequilibria between DNA-defined HLA class I alleles in five ethnic groups. European J of Immunogenetics 25:46, 1998. e-Pub 1998.
Burdett L, Cao K, Zhang GH, Fernández-Viña MA. Characterization of Novel HLA-B Locus alleles in the Retrospective Study of Bone Marrow Transplant Pairs Organized by the National Marrow Donor Program. Human Immunology 59(S1):22, 1998. e-Pub 1998.
Cao K, Yu J, Ellexson M, Hildebrand WH, Petersdorf EW, Smith AG, Setterholm M, Fernández-Viña MA. Retrospective Study of HLA-C Alleles in Donor and Recipient Samples Organized by the National Marrow Donor Program. Human Immunology 59(S1):24, 1998. e-Pub 1998.
Hollenbach JA, Fernández-Viña MA, Cao K, Erlich HA, Bugawan T, Klitz W. Strong Disequilibrium Found Across the Entire HLA Region in Mesoamerican Natives. Human Immunology 59(S1):57, 1998. e-Pub 1998.
Cao K, Yu J, Hollenbach JA, Burdett L, Hunter J, Klitz W, Fernández-Viña MA. DNA Typing of HLA-A, B, C Alleles in Three Amerindian Populations by PCR-SSOP. Human Immunology 59(S1):61, 1998. e-Pub 1998.
Cao K, Burdett L, Hollenbach JA, Yu J, Zhang GH, Hunter J, Klitz W, Fernández-Viña MA. New Alleles at HLA-B, -C Loci (B*1541, B*3523, B*3524, Cw*0305) Identified in Three Amerindian Tribes. Human Immunology 59(S1):62, 1998. e-Pub 1998.
Burdett L, Cao K, Zhang GH, Fernández-Viña MA. Novel Alleles Identified in HLA-A & B. Human Immunology 59(S1):62, 1998. e-Pub 1998.
Cao K, Noreen H, Yu J, Segall M, Hunter J, Pearson T, Cook D, Ellison MD, Wetszteon P, Ting A, Fernández-Viña MA. DNA Typing of HLA-Class I-A, B, C Genes by PCR-SSOP for Kidney Transplantation Donor-recipient Pairs of the United Network for Organ Sharing (UNOS) Program. Human Immunology 59(S1):91, 1998. e-Pub 1998.
Burdett L, Cao K, Fernández-Viña MA. Direct Sequencing of Class I B-locus. European J of Immunogenetics 25:46, 1998. e-Pub 1998.
Burdett L, Cao K, Zhang GH, Hewavitharana T, Fernández-Viña MA. Direct Sequencing of HLA B-Locus. Human Immunology 59(S1):148, 1998. e-Pub 1998.
Cao K, Yu J, Carter C, Assia M, Le T, Hunter J, Fernández-Viña MA. Routine HLA-A, B Intermediate Resolution Typing by PCR-SSOP. Human Immunology 59(S1):149, 1998. e-Pub 1998.
Cao K, Burdett L, Ellexson M, Hildebrand WH, Hunter J, Petersdorf EW, Smith AG, Turner S, Fernández-Viña MA. Novel alleles related to HLA-Cw*1601, Cw*0401 and Cw*0802 identified in the retrospective study of bone marrow transplant pairs organized by the National Marrow Donor Program (NMDP). Human Immunology 55(S1):129, 1997. e-Pub 1997.
Cao K, Shi XJ, Shi WX, Burdett L, Hunter J, Chopek M, Fernández-Viña MA. Analysis of the linkage disequilibria between DNA-defined HLA class I alleles in five ethnic groups. Human Immunology 55(S1):33, 1997. e-Pub 1997.
Burdett L, Cao K, Zhang GH, Hunter J, Chopek M, Fernández-Viña MA. Novel alleles identified in HLA-B and C loci. Human Immunology 55(S1):102, 1997. e-Pub 1997.
Turner S, Burdett L, Ellexson M, Cao K, Jacques C, Hunter J, Sellman J, Zhang Y, Hildebrand WH, Fernández-Viña MA. High resolution HLA-C typing: Homozygosity frequencies and detection of new alleles in 700 samples from the NMDP research repository. Human Immunology 55(S1):29, 1997. e-Pub 1997.
Burdett L, Cao K, Hunter J, Lazaro A, Marcos CY, Noreen H, Segall M, Stewart M, Stastny P, Fernández-Viña MA. Characterization of seven novel HLA-B alleles in the retrospective study of bone marrow transplant pairs organized by the National Marrow Donor Program (NMDP). Human Immunology 55(S1):130, 1997. e-Pub 1997.
Cao K, Nielsen J, Burdett L, Zhang GH, Hunter J, Chopek M, Fernández-Viña MA. Identification of novel alleles of HLA-A*68 group: A*6803, A*6804 and A*6805. Human Immunology 55(S1):105, 1997. e-Pub 1997.
Cao K, Spalding T, Hunter J, Chopek M. DNA Typing of HLA-A Alleles in Five Ethnic Groups by PCR-SSOP. Human Immunology 49(S1):32, 1996. e-Pub 1996.
Cao K, Shi WX, Stearman J, Patel A, Hunter J, Chopek M. DNA Typing of HLA-C Alleles in Five Ethnic Groups by PCR-SSOP. Human Immunology 49(Sl):33, 1996. e-Pub 1996.
Song FJ, Yin X, He WD, Cao K, Xiao Y, Zhang Q. Association between HLA and Dermatologic Diseases in Chinese. Human Immunology 49(S1):60, 1996. e-Pub 1996.
Nielsen J, Zhang GH, Cao K, Spalding T, Stearman J, Hunter J, Chopek M. Routine Cloning and DNA Sequencing of Class I Alleles. Human Immunology 49(S1):45, 1996. e-Pub 1996.
Han X, Song FJ, Xiao Y, Cao K. Study on Correlation between anaphylactoid Perpura and HLA in Chinese. Human Immunology 49(S1):68, 1996. e-Pub 1996.
Cao K, Nielsen J, Shi XJ, Zhang GH, Hunter J, Chopek M. DNA Typing of HLA-B Alleles: Comparison of PCR-SSOP and PCR-Cloning-Sequencing. Human Immunology 49(S1):47, 1996. e-Pub 1996.
Zimmerman P, Nielsen J, Cao K, Behm S, Chopek M. Genotypic Analysis of HLA Class I Loci Performed Efficiently by Heteroduplex Analysis. Human Immunology 44(S1):163, 1995. e-Pub 1995.
Cao K, Shi WX, Nielsen J, Stearman J, Chopek M. DNA Typing of HLA-A Using Polymerase Chain Reaction (PCR) and Sequence-Specific Oligonucleotide Probes (SSOP). Human Immunology 44(S1):151, 1995. e-Pub 1995.
Cao K, Shi WX, Stearman J, Hunter J, Chopek M. Locus Specific Intronic Primers for HLA-A, B, and C Loci. Human Immunology 44(S1):145, 1995. e-Pub 1995.
Nielsen J, Zhang G, Spalding T, Cao K, Hunter J, Chopek M. Molecular Cloning and Automated Sequences on a New HLA-DRB1 Allele within the DRB1*14 Family. Human Immunology 44(S1):52, 1995. e-Pub 1995.
Song FJ, Xu SY, Li HG, Xiao Y, He WD, Cao K, Su XH. Study on the application of monoclone antibody for treating malignant lymphoma. The 4th Annual Dermatology Meeting of Northeast Provinces of China, 1992. e-Pub 1992.
Li HG, Song FJ, Xu SY, Cao K, Xiao Y, He WD. Study of the function of HLA antigens on the identification of parents and offsprings. The 3rd Annual Dermatology Meeting of Northeast Provinces of China, 1991. e-Pub 1991.

Book Chapters

Cao, K, Zou, J, Fernandez-Vina, M. Role of the Human Leukocyte Antigen System in Hematopoietic Stem Cell Transplantation. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. 1st. Elsevier, 17-25, 2023.
Hurley, CK, Cao, K, Tang, T, Steiner, NK, Lazaro, A, Howard, CA, Ng, J. Molecular Methods: HLA Alleles. In: Manual of Molecular and Clinical Lab Immunology. 7th edition. John Wiley and Sons Inc, 1198-1214, 2022.
Kongtim P, Cao K, Ciurea SO. Anti-HLA Antibodies: Assessment and Mitigating Strategies. In: Haploidentical Transplantation. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham, 127-143, 2017.
Reinsmoen NL, Cao K, C-H L. Immunologic Disorders Autoimmunity: Genetics and Immunlogic Mechanisms. In: Emery and Rimoin's Principles and Practice of Medical Genetics. 6th. Elsevier Inc, Chapter 76:1763-1776, 2014.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with the antigen group A28 and its serologic splits A68 and A69. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 965-972, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with Cw5, 8, 12, 14, 16. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1083-1086, 2006.
Gutierrez M, Stoddard J, Machan C, Burdette L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with Cw7. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1087-1088, 2006.
Gutierrez M, Stoddard J, Machan C, Burdette L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with HLA-B13. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1091-1096, 2006.
Gutierrez M, Stoddard J, Machan C, Burdette L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with B37. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1097-1103, 2006.
Hurley CK, Cao K, Tang T, Steiner N, Lazaro AM, Howard HC, Ng J. Molecular Methods: HLA Alleles. In: Manual of Molecular and Clinical Laboratory Immunology. ASM Press, 1198-1214, 2006.
Yunis EJ, Larsen CE, Fernández-Viña M, Awdeh ZL, Cao K, Romero T, Cam A. Human MHC haplotypes and their fragments or blocks. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 54-64, 2006.
Hurley, CK, Hegland J, Fernández-Viña MA, Maiers MA, Lazaro A, Hartzman RJ, Cao K, Ng J, Janzen M, Setterholm M. Designing a Typing System for a Hematopoietic Stem Cell Registry. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 464-466, 2006.
Moormann AM, Cao K, Masaberg C, Sumba OP, Koech D, Ng J, Hartzman RJ, Kazura J, Fernández-Viña MA. Genetic Diversity Joint Report: Population Reports: Population: Luo and Nandi from Kenya. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 582, 2006.
Cao K, Lyke KE, Masaberg C, Doumbo OK, Ng J, Hartzman RJ, Plowe CV, Sztein MB, Fernández-Viña MA. Genetic Diversity Joint Report: Population Reports: Population: Malian admixed from Mali. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 583-584, 2006.
Cao K, Masaberg C, Yu J, Mann DL, Fernández-Viña MA. Genetic Diversity Joint Report: Population Reports: Populations: Ugandans from Kampala, Uganda and Zambians from Lusaka, Zambia. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 589-590, 2006.
Cao K, Fernández-Viña MA. Populations: African American, Caucasian, Hispanic, Asian Pacific Islander and Native American from the United States. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 648-651, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with the specificity HLA-A2. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 949-952, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with the specificities A23 and A24. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 953-958, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viñ MA. Report of the serologic reactivity of alleles associated with the specificities B35, B51, B52, B53 and B78. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 973-996, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with the B12 antigen group (B44, B45) and the B21 antigen group (B49 and B50). In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop & Conference. IHWG Press, 997-1003, 2006.
Yunis EJ, Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with the specificities HLA-B7, B42, B73, B81, B82 and B22. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1010-1016, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viñ MA. Report of the serologic reactivity of alleles associated with the B40 antigen groups B40 and its serologic splits B60 and B61. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1038-1042, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with HLA-B41. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1043-1045, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with HLA-B47. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1046-1050, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with HLA-B48. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1051-1054, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic Epitopes associated with specificities Bw4 and Bw6. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1070-1072, 2006.
Gutierrez M, Stoddard J, Machan C, Burdett L, Cao K, Hartzman RJ, Fernández-Viña MA. Report of the serologic reactivity of alleles associated with Cw4, Cw6. In: Immunology of the Human MHC, Proceedings of the 13th International Histocompatibility Workshop and Conference. IHWG Press, 1079-1082, 2006.
Fernández-Viña MA, Cao K, Middleton D. Molecular HLA Typing, HLA: The Major Histocompatibility Complex. In: Clinical Laboratory Medicine. Lippincott, Williams & Wilkins Awolters Kluwer Company, 754-762, 2002.
Song FJ, Cao K. Dermatology and Dermatological sex-transmitted Diseases. In: Textbook for Chinese rural doctors. Publishing House of People’s Health, 1992.
Cao K, Song FJ. Study aid (2) for Dermatology. In: Chinese Rural Medicine J, 59-64, 1991.
Cao K, Song FJ. Study Aid (1) for Dermatology. In: Chinese Rural Medicine J, 40-46, 1990.
Song FJ, Cao K. Dermatology. In: Textbook for Chinese Rural Doctors. Publishing House of People’s Health, 1989.

Letters to the Editor

Ciurea SO, Cao K, Zou J. Donor-specific anti-HLA antibodies and …recipient-specific anti-HLA antibodies? The conundrum on pregnancy in transplantation. Am J Hematol, 95: E128-E130, 2020.
Cao K, Ciurea SO. Reply to: Use of Single-Antigen Flow Beads Assays to Assess Anti-HLA Donor-Specific Antibody Strength. Biology of Blood and Marrow Transplantation 22 2016: 395-396, 2016.

Less

CV information above last modified March 26, 2026

Kai Cao, MS, MD, F(ACHI)

About Dr. Kai Cao

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Kai Cao, MS, MD, F(ACHI)

About Dr. Kai Cao

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson